T. El Gnaoui

Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.

C. Copie-Bergman, J. Jais, A. Rahmouni, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria.

C. Copie-Bergman, A. Rahmouni, C. Gisselbrecht, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial

P. Gaulard, G. Salles, A. Rahmouni, 2013, Haematologica.

Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation

F. Jardin, P. Gaulard, H. Tilly, 2021, Leukemia & lymphoma.

Respective prognostic values of germinal center phenotype and early (18)fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma.

C. Copie-Bergman, P. Gaulard, A. Rahmouni, 2007, Haematologica.

Clinical relevance of flow cytometric immunophenotyping of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma.

C. Copie-Bergman, P. Brugières, C. Haioun, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Rituximab in combination with CHOP regimen in T-cell angioimmunoblastic lymphoma (AILD-TL) rich in large B cells. Favourable results in four patients.

P. Gaulard, A. Rahmouni, C. Haioun, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies

F. Lemonnier, C. Haioun, S. Gallien, 2022, Clinical Microbiology and Infection.